DARK Daily Laboratory and Pathology NewsDARK Daily is an e-briefing service providing up-to-the minute news of relevance for anyone working in diagnostic medicine, from clinical laboratories and pathology groups to lab industry suppliers and diagnostic technology companies. DARK Daily is part of The Dark Intelligence Group, Inc. and is dedicated to bringing useful business and management intelligence to laboratory managers, pathologists and diagnostic executives. Our recognized expertise in the strategic direction of laboratory medicine and the management of laboratories is available through DARK Daily, The Dark Report, free White Papers, Lab Resource Directory, the Executive War College on Laboratory and Pathology Management, Lab Quality Confab, and strategic consulting services.
Genomic Study Reveals Role of Human Papillomavirus in Cervical Cancer and Identifies Novel Therapeutic Targets for the Disease
Findings may help physicians tailor cervical cancer therapies to specific gene mutations and improve the accuracy of diagnostic screening tests for this disease
New scientific knowledge about the role of human papillomavirus (HPV) in the growth of cervical cancer is creating excitement within the medical community. Among other things, these findings could encourage more widespread vaccination against HPV. That in turn would lead to reduced Pap smear testing by pathology laboratories over time.
For these reasons, cytopathologists and cytotechnologists will be particularly interested in the research findings that were published as a first-ever, international genomic study of cervical cancer, which was published online December 25, 2013, at Nature.com. Researchers discovered that the location where HPV integrates itself into the human genome, is where it causes amplified gene expression that promotes and elevates mutated gene activity that may cause cervical cancer to develop. continue reading
Is Illumina’s $1,000 Genome a Realty? Not for Clinical Laboratory Purposes, Asserts an In Vitro Diagnostics Expert
Gene sequencing for clinical purposes requires more resources, including the costs of experts to interpret data to help pathologists and physicians involved in the case
It was January when headlines nationwide trumpeted Illumina’s introduction of the $1,000 genome. The story in Forbes Magazine, “The $1,000 Genome Arrives—For Real, This Time,” was typical of much of the press coverage.
Because pathology groups and clinical laboratories have much at stake in the race to the $1,000 whole-human genome sequence, it is important to know the real facts about the cost and performance of Illumina’s latest generation of genome sequencing technology. After all, corporate press releases are intentionally designed to present a company’s product in the best possible light. continue reading
Ratings Agencies Go Negative on Not-for-Profit Hospitals for 2014; Their Projections Signal Fewer Resources for Hospital-based Clinical Laboratories
This hospital industry sector is expected to achieve lower growth rates and less revenue and are likely to reduce operating budgets for medical laboratories
Tough financial times are ahead for not-for-profit hospitals, according to the projections of multiple rating agencies. Financial analysts attribute this to an extended period of massive and disruptive change. This is not good news for hospital-based clinical laboratory managers and pathology groups.
Big Three credit-rating agencies Moody’s Investors Service (NYSE: MCO), Fitch Ratings, and Standard & Poor’s Financial Services LLC (S&P) echoed a common theme in their 2014 outlooks for not-for-profit hospitals, which represent 60% of the nation’s hospitals. Environmental pressures will suppress revenue growth, while fresh cost-cutting measures will become increasingly harder to find. continue reading
Study Shows How Simple Changes in Reporting Medical Laboratory Test Results to Clinicians Improve Patient Safety and Reduce Inappropriate Use of Antibiotics
Researchers focused on whether different ways of reporting clinical laboratory test results would improve care for patients at low risk for developing urinary tract infections
Simple changes in how clinical laboratory tests are reported to clinicians can contribute to improved patient safety and a reduction in the inappropriate use of antibiotics. These were the conclusions of a recent study published in the Infectious Diseases Society of America’s (IDSA) peer-reviewed medical journal, Clinical Infectious Diseases (CID).
If the findings of this study can be duplicated in other settings, it can provide pathologists and medical laboratory scientists with another approach to improve the way clinicians utilize clinical laboratory tests so as to improve patient outcomes and reduce the associated cost of care. continue reading
Congress Passes Law Changing How Medicare Sets Prices for Clinical Laboratory Tests; Lab Industry Groups Differ on Which Labs Will Be Winners and Losers
Leaders from ACLA, AdvaMedDx, CAP, NILA will be at Executive War College on April 29-30 for first medical lab industry debate about the best and worst of the new law
Clinical laboratories will face new financial challenges following passage of a new federal law two weeks ago that makes deep changes in the way Medicare officials will establish prices for the Medicare Part B Clinical Laboratory Fee Schedule (CLFS). Many medical laboratory administrators, hospital lab managers, and pathologists remain unaware of the significant negative financial impact this law will have on their lab’s revenue and fiscal stability.
On April 1, President Barack Obama signed H.R. 4302: Protecting Access to Medicare Act of 2014. The law’s primary purpose is to extend the Sustainable Growth Rate (SGR) formula for 12 months. The House had passed the bill on the previous Thursday and the Senate passed the bill on the following Monday, March 31. continue reading
DARK Daily is a free e-briefing service that provides one short, easy-to-read news item every weekday, highlighting noteworthy developments in the clinical laboratory industry. First alerts to important news events, incisive assessment of best-practice breakthroughs, and strategic insights on important trends make these e-briefings timely and invaluable. Sign up for the DARK Daily today and receive the special report Trends In Clinical Pathology Laboratory Management free.
The Dark Report
Since its founding in 1995, The Dark Report has been the laboratory industry’s most reliable source for useful business intelligence and innovations in the management of clinical laboratories and pathology group practices. Widely-read and much discussed, The Dark Report is respected as a source of knowledge and information that allows lab administrators, pathologists, and industry executives to be first to learn about the latest facts and trends that affect medical laboratories of all kinds.
With a demonstrated track record of success, Robert Michel and the team at The Dark Intelligence Group, Inc. deliver strategic insight and market analysis that directly leads to increased revenues, improved profitability, and operational excellence. Having continuously worked with and visited laboratories, pathology groups, and lab industry vendors for more than 12 years, Robert Michel brings a unique set of skills and experience to any strategic challenge or opportunity.
Energize your next public meeting, strategic retreat, or corporate event. Widely-recognized and often asked back for a second and third year, Robert Michel has a recognized ability to help audiences get more from the speakers and advance their knowledge and understanding about key trends and management innovations. One- and two-day management retreats are a specialty.
For a dynamic and knowledgeable public speaker to turbo-charge your next meeting, contact The Dark Intelligence Group. When it comes to management of clinical laboratories and pathology group practices, Robert Michel and his colleagues are consistently ranked among the industry’s keenest minds.